Unpacking Q1 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) In The Context Of Other Therapeutics Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let's take a look at how therapeutics stocks fared in Q1, starting with Vertex Pharmaceuticals (NASDAQ:VRTX).
Over the next few years, therapeutic companies, which develop a wide variety of treatments for diseases and disorders, face strong tailwinds from advancements in precision medicine (including the use of AI to improve hit rates) and growing demand for treatments targeting rare diseases. However, headwinds such as rising scrutiny over drug pricing, regulatory unknowns, and competition from larger, more resourced pharmaceutical companies could weigh on growth.
The 10 therapeutics stocks we track reported a mixed Q1. As a group, revenues beat analysts' consensus estimates by 1.2%.
Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 10.5% since the latest earnings results.
Founded in 1989 with a mission to create medicines that treat the underlying causes of disease rather than just symptoms, Vertex Pharmaceuticals (NASDAQ:VRTX) develops and markets transformative medicines for serious diseases, with a focus on cystic fibrosis, sickle cell disease, and pain management.
Vertex Pharmaceuticals reported revenues of $2.77 billion, up 3% year on year. This print fell short of analysts' expectations by 2.3%. Overall, it was a disappointing quarter for the company with a significant miss of analysts' EPS estimates and full-year revenue guidance slightly missing analysts' expectations.
'Vertex delivered a strong start to 2025 with notable execution across the business as we grow and diversify the revenue base, progress multiple launches and advance the R&D pipeline. We continued to expand our leadership in CF and build global momentum for CASGEVY, and we launched JOURNAVX in moderate-to-severe acute pain,' said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex.
Unsurprisingly, the stock is down 14.1% since reporting and currently trades at $429.37.
Read our full report on Vertex Pharmaceuticals here, it's free.
Founded by a mother seeking treatment for her daughter's pulmonary arterial hypertension, United Therapeutics (NASDAQ:UTHR) develops and commercializes medications for chronic lung diseases and other life-threatening conditions, with a focus on pulmonary hypertension treatments.
United Therapeutics reported revenues of $794.4 million, up 17.2% year on year, outperforming analysts' expectations by 5.6%. The business had an exceptional quarter with an impressive beat of analysts' EPS estimates.
The market seems content with the results as the stock is up 2.7% since reporting. It currently trades at $308.
Is now the time to buy United Therapeutics? Access our full analysis of the earnings results here, it's free.
Founded in 1991 as one of the pioneers in translating genetic discoveries into clinical applications, Myriad Genetics (NASDAQ:MYGN) develops genetic tests that assess disease risk, guide treatment decisions, and provide insights across oncology, women's health, and mental health.
Myriad Genetics reported revenues of $195.9 million, down 3.1% year on year, falling short of analysts' expectations by 2.3%. It was a softer quarter as it posted full-year revenue guidance missing analysts' expectations.
As expected, the stock is down 44.7% since the results and currently trades at $4.01.
Read our full analysis of Myriad Genetics's results here.
Rising to global prominence during the COVID-19 pandemic with one of the first effective vaccines, Moderna (NASDAQ:MRNA) develops messenger RNA (mRNA) medicines that direct the body's cells to produce proteins with therapeutic or preventive benefits for various diseases.
Moderna reported revenues of $108 million, down 35.3% year on year. This result lagged analysts' expectations by 8.4%. It was a softer quarter as it also produced full-year revenue guidance missing analysts' expectations.
Moderna had the weakest performance against analyst estimates, slowest revenue growth, and weakest full-year guidance update among its peers. The stock is down 14.5% since reporting and currently trades at $24.44.
Read our full, actionable report on Moderna here, it's free.
Born from a 2013 spinoff of Abbott Laboratories' pharmaceutical business, AbbVie (NYSE:ABBV) is a biopharmaceutical company that develops and markets medications for autoimmune diseases, cancer, neurological disorders, and other complex health conditions.
AbbVie reported revenues of $13.34 billion, up 8.4% year on year. This number surpassed analysts' expectations by 3.3%. Overall, it was a very strong quarter as it also recorded an impressive beat of analysts' constant currency revenue estimates and a decent beat of analysts' EPS estimates.
The stock is up 3% since reporting and currently trades at $185.99.
Read our full, actionable report on AbbVie here, it's free.
Thanks to the Fed's rate hikes in 2022 and 2023, inflation has been on a steady path downward, easing back toward that 2% sweet spot. Fortunately (miraculously to some), all this tightening didn't send the economy tumbling into a recession, so here we are, cautiously celebrating a soft landing. The cherry on top? Recent rate cuts (half a point in September 2024, a quarter in November) have propped up markets, especially after Trump's November win lit a fire under major indices and sent them to all-time highs. However, there's still plenty to ponder — tariffs, corporate tax cuts, and what 2025 might hold for the economy.
Want to invest in winners with rock-solid fundamentals? Check out our Hidden Gem Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.
Join Paid Stock Investor Research
Help us make StockStory more helpful to investors like yourself. Join our paid user research session and receive a $50 Amazon gift card for your opinions. Sign up here.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
These Artificial Intelligence (AI) Stocks Are Quietly Outperforming the Market
Two AI stocks have crushed the broader market in the past year, and they seem primed for more upside. Fast-growing demand for AI tools in cloud-based services is helping these companies attract new customers. 10 stocks we like better than Twilio › Artificial intelligence (AI) stocks have been in fine form on the market in the past few years, and that's not surprising, as this technology has supercharged the growth of many companies. Thanks to huge investments in AI hardware such as semiconductors, as well as the rapidly growing adoption of AI software to boost productivity, it is estimated that overall spending on AI could hit a massive $628 billion by 2028. This explains why investors have been buying AI stocks hand over fist. However, there are certain AI stocks that have significantly outpaced the broader stock market, and importantly, they still have the potential to deliver more upside. Let's take a closer look at these two names that aren't all that popular, but have been outperforming the market in the past year. Twilio (NYSE: TWLO) stock is up an impressive 115% in the past year as of this writing, easily outperforming the 11% gains clocked by the Nasdaq Composite over the same period. The good part is that Twilio still trades at an attractive 26 times forward earnings and 4 times sales, even after its terrific surge in the past year. The valuation makes buying Twilio stock a no-brainer right now, especially considering how AI now plays an important role in accelerating its growth. Twilio's application programming interfaces (APIs) allow its clients to connect with their customers through various channels such as voice, text, email, video, chat, and others. Twilio points out that its customer engagement platform is used by more than 300,000 enterprises globally. Specifically, the company ended the first quarter of 2025 with more than 335,000 active customer accounts, an increase of 7% from the previous year. This huge customer base is a key reason why one can consider buying Twilio stock right now, as it gives the company the opportunity to cross-sell its AI offerings to a big pool of customers. Twilio has been offering multiple AI tools to customers, such as generative AI-powered assistants that can help tackle customer service queries autonomously, integrating human-like conversational AI assistants to talk to customers in real time and derive critical insights from customers' data with the help of AI. The growing demand for these AI services helps Twilio win more business from existing customers. This is evident from the five-percentage-point jump in fiscal 2025 Q1's dollar-based net expansion rate compared to the first quarter of 2024. The higher customer spending, along with an increase in Twilio's customer base, are the reasons why it has raised its full-year organic revenue growth guidance to 8% from the earlier forecast of 7.5%. This combination of higher customer spending, along with an increase in the customer count, explains why analysts expect a 24% increase in Twilio's earnings this year, followed by impressive growth over the next couple of years as well. Assuming Twilio indeed generates $6.21 per share in earnings after a couple of years and trades at 30 times earnings at that time (in line with the tech-laden Nasdaq-100 index's forward earnings multiple), its stock price could jump to $186. That would be a 59% jump from current levels. So, investors can expect more upside from this AI stock going forward, which is why it would be a smart idea to consider buying it while it trades at attractive levels. Snowflake (NYSE: SNOW) share prices have jumped an impressive 64% in the past year despite bouts of volatility, and a closer look at the price chart will tell us that the stock has made a sharp move up in the past couple of months. Importantly, more upside in Snowflake stock cannot be ruled out, as fast-growing adoption of the company's AI-focused data cloud tools is helping it build a robust revenue pipeline for the future. Snowflake's data cloud platform enables customers to safely store their data in a single platform, which can then be used to derive insights and build applications. The company's AI-specific tools are now helping customers get more out of their data. They can apply large language models (LLMs) to their data to build applications such as AI agents, generative AI assistants, and search documents through natural language prompts, among other things. These offerings are turning out to be a hit among Snowflake customers, with nearly 45% of its 11,600-strong customer base using its AI tools every week in the previous quarter. Additionally, AI is helping Snowflake attract more customers. This is evident from the 19% year-over-year increase in its customer count in Q1 of fiscal 2026. This combination of an increase in Snowflake's customer base, along with the growing adoption of its AI tools, is the reason why its remaining performance obligations (RPO) increased by an impressive 34% year over year in the previous quarter to $6.7 billion, which was better than the 26% growth in its product revenue to just under $1 billion. The strong growth in its revenue pipeline encouraged management to increase its fiscal 2026 revenue guidance as well. What's more, Snowflake's earnings are expected to increase by a third in the current fiscal year to $1.10 per share. Consensus estimates project faster growth over the next couple of fiscal years. That won't be surprising, as Snowflake's ability to win more business from its existing customers and an improvement in its overall customer count should allow it to continue improving its revenue pipeline, especially considering that it sees its total addressable market growing to a whopping $342 billion in 2028. In all, Snowflake investors can expect more upside from this cloud stock following the impressive gains that it has delivered in the past year, driven by a new catalyst in the form of AI. Before you buy stock in Twilio, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Twilio wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $659,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $891,722!* Now, it's worth noting Stock Advisor's total average return is 995% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Harsh Chauhan has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Snowflake and Twilio. The Motley Fool has a disclosure policy. These Artificial Intelligence (AI) Stocks Are Quietly Outperforming the Market was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
35 minutes ago
- Yahoo
Palantir (PLTR) Director, Eric H. Woersching, Sells Shares Valued at $2.2 Million
Palantir Technologies Inc. (NASDAQ:PLTR) is one of the . An SEC filing revealed that Palantir director, Eric H. Woersching, sold nearly $2.2 million worth of his shares on June 10. A total of 17,000 Class A common shares were sold on June 9, 2025, priced between $125.24 and $131.70 per share. The sale follows PLTR trading close to its 52-week high of $135.28, with a whopping 456.81% return over the last year. The shares were sold under a pre-established Rule 10b5-1 trading plan, which was formalized on March 10, 2025. This plan enables insiders of publicly traded corporations to establish a trading plan for disposing of stocks they own, following insider trading laws. A software engineer manipulating a vast network of code on virtual monitors. Before these sales, Woersching secured 2,348 restricted shares on June 6, 2025, as a yearly award for his position on the board of directors. These restricted units were offered with no financial exchange, reflecting a contingent right to obtain shares according to a vesting schedule. After these transactions, Eric Woersching owns 12,562 Palantir shares. Palantir Technologies Inc. (NASDAQ:PLTR) develops software platforms that help governments and businesses make sense of complex data, supporting counterterrorism efforts, enterprise operations, and AI-driven decision-making. While we acknowledge the potential of PLTR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure. None. Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Should PayPal be on my list of shares to buy?
On the face of it, PayPal (NASDAQ:PYPL) ought to be on my list of shares to buy. The company has a market value of $69bn and has generated just under $6bn in free cash in the last year. With minimal debt, that implies a free cash flow yield of almost 9%. That's pretty high considering the business isn't in decline – but there's a catch when it comes to the valuation. With no dividend, PayPal returns cash to shareholders via share buybacks. These work by reducing the outstanding share count, increasing the value of each of the remaining shares. Since 2020, PayPal's returned over $20bn via share repurchases. That's around 30% of its current market value and the returns have been going up. Year Share Buybacks 2024 $6bn 2023 $5bn 2022 $4.2bn 2021 $3.4bn 2020 $1.6bn Despite this, the company's share count has only fallen by about 13% over the last five years. That's much less impressive and it raises an important question for investors. PayPal's share count isn't really going down much despite the firm using almost all the free cash it generates to buy back shares. So where's the money going? A big part of the answer is stock-based compensation. This is where PayPal issues shares to pay its staff part of their salaries in the firm's stock, rather than cash. A lot of companies do this and I don't think there's anything intrinsically wrong with it. But it's something that investors need to factor into their calculations. Since 2020, PayPal's issued around $6.5bn in stock to cover these expenses. And this has gone some way towards offsetting the cash the firm's been using for share buybacks. In 2024, the company spent almost $6bn on repurchasing shares, but just over 20% of this was offset by stock-based compensation. So the outstanding share count only fell by around 6%. Stock-based compensation doesn't involve cash leaving the business directly. As a result, some investors tend to think it isn't a real expense. I however, think this is a mistake. Issuing equity automatically reduces the value of share buybacks and this is a key mechanism companies can return cash to shareholders. This is especially true when it comes to PayPal. Its 9% free cash flow yield's attractive at first sight, but the firm can't just use this to bring down its share count by that amount every year. Before it can start bringing down its number of shares outstanding, it has to buy back the ones it issued. And it has to do that with cash, making it a very real expense for investors. I don't think PayPal's stock-based compensation is a reason to dismiss the stock out of hand immediately. And the company's undergoing an interesting shift in terms of its priorities. Focusing on margins over revenue growth could boost profits and integrating further into the online transaction process could boost its competitive position. These are potential positives. For the time being though, I think there are better opportunities available. While the stock looks like a bargain at first sight, I don't think it's as attractive for me as it seems. The post Should PayPal be on my list of shares to buy? appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool Stephen Wright has no position in any of the shares mentioned. The Motley Fool UK has recommended PayPal. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
